JOURNAL OF CLINICAL AND FUNDAMENTAL MEDICAL RESEARCH
VOLUME-1, ISSUE-5, 2026

# Development and Justification of Therapeutic Approaches for Abnormal Uterine Bleeding in Puberty

**Diyora Farkhodjon kizi Pulatova**
1st-Year Master's Student
**Docent Nilufar Makhmudovna Akhmedova**
Scientific Supervisor Department of Obstetrics and Gynecology, Andijan State Medical Institute

## Abstract

Abnormal uterine bleeding during the pubertal transition represents a profound pediatric and adolescent gynecological emergency, frequently precipitating severe hemodynamic instability, profound iron deficiency anemia, and extensive psychobehavioral distress. This prospective cohort investigation evaluates and standardizes etiology-driven therapeutic interventions for adolescent females experiencing acute and chronic heavy menstrual bleeding. Analyzing a strictly phenotyped cohort of 312 patients aged 11 to 17 years admitted between 2020 and 2024, the study quantifies the clinical efficacy of tiered pharmacological strategies, including targeted antifibrinolytic therapy, non-steroidal anti-inflammatory drugs, and specific hormonal regimens. Clinical parameters, encompassing Pictorial Blood Loss Assessment Chart scores, hemoglobin kinetics, coagulation cascades, and pelvic ultrasonography morphometrics, were synthesized using multivariate logistic regression frameworks. The etiological breakdown identified anovulatory dysfunction secondary to hypothalamic-pituitary-ovarian axis immaturity as the predominant driver (65.4%), while underlying systemic coagulopathies accounted for a highly significant secondary subset (19.2%). The therapeutic analysis demonstrated that initial intervention utilizing intravenous tranexamic acid combined with high-dose oral progestins arrested acute hemorrhagic episodes within 36 hours in 84.6% of patients, circumventing the need for surgical hemostasis entirely. Long-term stabilization using combined oral contraceptives yielded a 91.2% success rate in

preventing recurrent hospital admissions over a 12-month follow-up period, outperforming sequential progestin therapies. These findings mandate an immediate departure from generalized adult gynecological protocols. Recognizing the unique neuroendocrine and hematological vulnerabilities of the adolescent patient requires the deployment of age-specific, etiology-based algorithms, directly optimizing acute hemostatic recovery and safeguarding long-term reproductive potential.

**Keywords:** Abnormal uterine bleeding; Pubertal gynecology; Hypothalamic-pituitary-ovarian axis; Heavy menstrual bleeding; Antifibrinolytic therapy; Endometrial hemostasis; Von Willebrand disease.

## Introduction

The onset of menarche initiates a highly complex, protracted maturation phase within the adolescent neuroendocrine system. During this developmental window, the structural and functional coordination of the hypothalamic-pituitary-ovarian axis remains inherently unstable, frequently resulting in prolonged intervals of unopposed estrogen exposure and anovulatory cycling. Consequently, abnormal uterine bleeding in puberty emerges as a dominant pathological entity, accounting for over half of all acute gynecological admissions within the pediatric demographic. The physiological failure to produce adequate progesterone prevents the synchronous stabilization and shedding of the endometrial lining, precipitating erratic, prolonged, and often massive hemorrhagic episodes.

Despite the high prevalence of this condition, contemporary clinical management frequently defaults to empirical, reactionary interventions modeled heavily on adult protocols. Adult-centric paradigms routinely fail to account for the unique physiological architecture of the adolescent reproductive system. A substantial proportion of pubertal bleeding episodes unmasks latent, hereditary bleeding disorders, such as von Willebrand disease or distinct platelet function defects, which remain entirely asymptomatic until menarche. Treating these hemato-oncological phenotypes with standard hormonal

manipulation provides only transient relief and fails to address the underlying coagulation defect. The absence of a rigidly defined, etiology-specific triage algorithm leads to delayed hemostasis, severe hypovolemic complications, and an over-reliance on aggressive blood transfusions.

The primary objective of this investigation is to construct and validate a highly precise, step-wise therapeutic protocol specifically engineered for the pubertal demographic. By systematically categorizing patients based on their primary physiological deficit—whether strictly neuroendocrine immaturity or a previously undiagnosed systemic coagulopathy—this study seeks to quantify the exact clinical response rates to distinct pharmacological agents. Establishing a strictly evidence-based therapeutic hierarchy will directly inform clinical decision-making, shifting the treatment paradigm from symptom suppression to targeted physiological correction.

**Materials and Methods**

To capture the varied therapeutic responses within the adolescent demographic, a prospective cohort design was executed, encompassing clinical data from 312 female patients treated for abnormal uterine bleeding. The observational window spanned from January 2020 to January 2024. Participant selection utilized stringent inclusion criteria: patients aged 11 to 17 years, presenting with a documented history of heavy menstrual bleeding defined by a Pictorial Blood Loss Assessment Chart score exceeding 100 points per cycle, or presenting acutely with acute hemorrhagic instability. Patients presenting with distinct structural anomalies, including active pelvic inflammatory disease, suspected malignancies, or documented pregnancy, were systematically excluded to eliminate anatomical variables in the therapeutic assessment.

The formalized cohort was stratified into specific analytical groups based on the severity of the initial presentation and the underlying etiology identified during the diagnostic workup. The diagnostic protocol mandated a comprehensive complete blood count, reticulocyte count, ferritin levels, and a full coagulation profile including partial

thromboplastin time, prothrombin time, and von Willebrand factor antigen assays. Pelvic ultrasonography was conducted universally to evaluate endometrial thickness and exclude occult structural lesions. Group 1 consisted of patients presenting with acute, severe bleeding requiring immediate hospital admission (n = 118). Group 2 comprised patients with chronic, heavy menstrual bleeding managed primarily in the outpatient setting (n = 194).

Therapeutic interventions were applied in a strict, escalating hierarchy. Acute management utilized intravenous tranexamic acid (10 mg/kg) alongside high-dose monophasic combined oral contraceptives or oral norethindrone acetate. Maintenance therapy included non-steroidal anti-inflammatory drugs, scheduled antifibrinolytics, or cyclical hormonal stabilization. Data synthesis utilized SPSS Statistics version 28.0. Continuous variables demonstrating normal distribution were analyzed using one-way Analysis of Variance, presenting data as mean +/- standard deviation (M +/- SD). The independent efficacy of specific pharmacological regimens on the probability of achieving complete hemostasis within 48 hours was calculated using multivariate logistic regression models. Statistical significance was rigidly established at a threshold of $p < 0.05$ across all analytical phases.

**Results**

The analytical extraction yielded profound insights into the etiology and pharmacological responsiveness of pubertal uterine bleeding. The initial phase of the analysis focused on the absolute diagnostic breakdown of the cohort. Anovulatory dysfunction resulting from neuroendocrine immaturity constituted the vast majority of cases, accounting for 65.4% of the population. A highly significant secondary etiology emerged in the form of underlying coagulopathies, representing 19.2% of the total cohort, with type 1 von Willebrand disease identified as the primary driver in 78% of these specific hematological cases. The remaining 15.4% of patients presented with diverse endocrine disruptions, including subclinical hypothyroidism and polycystic

ovary syndrome phenotypes. Baseline morbidities were severe across all groups; the mean hemoglobin concentration at initial presentation was 8.4 +/- 1.6 g/dL, with 42.6% of the cohort meeting the criteria for severe iron deficiency anemia requiring immediate intravenous iron sucrose infusion.

The second analytical phase evaluated the efficacy of acute hemostatic interventions within the hospitalized subgroup (Group 1). Patients subjected to a combined regimen of intravenous tranexamic acid and high-dose oral progestins (norethindrone acetate 5 mg every 6 hours) demonstrated an extraordinarily rapid cessation of hemorrhage. Within this specific intervention arm, 84.6% of patients achieved complete hemostasis within 36 hours of the initial dose. Conversely, patients treated solely with standard-dose combined oral contraceptives required an average of 52.4 +/- 8.2 hours to achieve comparable hemostatic stability ($p = 0.012$). The integration of systemic antifibrinolytic therapy reduced the total volume of acute blood loss by 46.2% within the first 48 hours of admission compared to historical, hormone-only protocols. None of the patients in the optimized therapy arm required surgical intervention, such as dilation and curettage, validating the efficacy of the aggressive medical management strategy.

The final phase quantified long-term therapeutic stabilization and relapse prevention over a 12-month follow-up period. Within the chronic management cohort (Group 2), the application of continuous or extended-cycle monophasic combined oral contraceptives yielded a 91.2% success rate in preventing recurrent hemorrhagic episodes. Patients utilizing cyclical oral progestins (administered from day 14 to 28 of the cycle) experienced a higher clinical failure rate, with 28.4% requiring a secondary intervention due to breakthrough bleeding. Logistic regression modeling confirmed that after adjusting for baseline endometrial thickness and body mass index, the utilization of a levonorgestrel-releasing intrauterine system in refractory cases independently increased the probability of maintaining long-term amenorrhea or light spotting by a factor of 4.15 (95% CI: 2.88-5.92, $p < 0.001$) compared to sequential oral therapies.

**Discussion**

The clinical realities extracted from this adolescent cohort unequivocally demonstrate that pubertal abnormal uterine bleeding cannot be managed through simplified, singular pharmacological pathways. The high prevalence of underlying coagulopathies (19.2%) identified in our population aligns fundamentally with the epidemiological parameters published by the North American Society for Pediatric and Adolescent Gynecology in 2022. Their multi-center analysis revealed that approximately 20% of adolescents presenting with severe menorrhagia harbor an inherited bleeding disorder. Our data localizes this phenomenon, proving the absolute necessity of integrating a comprehensive hematological workup into the first-line diagnostic algorithm before initiating long-term hormonal suppression. Failing to identify these defects leaves the patient vulnerable to severe hemorrhagic complications during future surgical or obstetric events.

When comparing the hemostatic efficacy of our acute intervention protocols against recent European cohorts analyzed by the International Federation of Gynecology and Obstetrics, a distinct kinetic advantage emerges. The European data indicated a standard 48 to 72-hour window for acute bleeding cessation using conjugated equine estrogens. Our cohort demonstrated a significantly accelerated timeline of 36 hours utilizing high-dose progestins combined with tranexamic acid. Because the anovulatory adolescent endometrium is highly estrogenized, fragile, and prone to spontaneous shedding, the aggressive introduction of a potent progestin rapidly stabilizes the stromal architecture and halts angiogenesis. Simultaneously, the tranexamic acid competitively inhibits plasminogen activation, directly neutralizing the excessive local fibrinolysis characteristic of heavy menstrual bleeding.

The superiority of extended-cycle combined oral contraceptives in preventing long-term relapse represents a critical finding regarding maintenance therapy. Cyclical progestin regimens, while theoretically replicating the physiological luteal phase, frequently fail

to maintain sufficient endometrial atrophy in the adolescent patient, leading to unpredictable breakthrough bleeding and poor medical compliance. The continuous provision of both an estrogen and a progestin completely suppresses the hyperactive, uncoordinated hypothalamic signaling, inducing a state of controlled endometrial pseudopregnancy.

Methodological limitations must be acknowledged when interpreting these therapeutic outcomes. The prospective design required rigorous patient compliance with oral regimens, which inherently fluctuated within the adolescent demographic. Additionally, the evaluation of the levonorgestrel-releasing intrauterine system was limited to a relatively small subset of refractory cases, necessitating larger, randomized controlled trials to fully validate its first-line utility in the pediatric population. Future investigations must integrate advanced genomic screening to identify specific polymorphisms in estrogen and progesterone receptors that dictate variable responses to standard hormonal therapies.

**Scientific Novelty and Practical Significance**

This investigation pioneers a highly precise, tiered therapeutic algorithm specifically engineered for the unique neuroendocrine and physiological architecture of the adolescent female. By quantifying the exact success rates of combined antifibrinolytic and high-dose progestin therapies, the study provides a definitive, evidence-based alternative to outdated estrogen-heavy protocols. The practical implications of these findings demand immediate integration into pediatric emergency and outpatient gynecological practices. Deploying this etiology-driven approach ensures rapid hemostatic recovery, drastically reduces the reliance on blood transfusions, and provides a structured, long-term stabilization pathway that actively preserves the patient's future reproductive potential and immediate psychological well-being.

**Conclusion**

Redefining the management of abnormal uterine bleeding in puberty requires an uncompromising commitment to etiology-specific triage. The biological divergence between simple anovulatory immaturity and latent systemic coagulopathies dictates entirely different immediate and long-term pharmacological requirements. Treating these distinct physiological crises with generalized adult protocols guarantees suboptimal clinical outcomes and high recurrence rates. Healthcare systems must strategically adopt the validated therapeutic hierarchy outlined in this investigation, prioritizing early hematological screening and the aggressive utilization of combined antifibrinolytic and progestin-driven hemostasis. Implementing this specialized, adolescent-focused algorithm transforms clinical care from reactive symptom management into a calculated, highly effective physiological stabilization, securing a definitive advantage in the protection of pediatric reproductive health.

**References**

1. Deligeoroglou E, Karountzos V. Management of abnormal uterine bleeding in adolescents: a comprehensive review. Pediatr Endocrinol Rev. 2021;18(3):234-245.
2. Mullins E, Gurtcheff S, Rebar R. The neuroendocrine regulation of the pubertal transition and its clinical implications. J Pediatr Adolesc Gynecol. 2022;35(2):112-120.
3. James AH. Heavy menstrual bleeding in adolescents with bleeding disorders. Haemophilia. 2020;26(1):15-22.
4. American College of Obstetricians and Gynecologists. Committee Opinion No. 785: Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding. Obstet Gynecol. 2019;134(3):e71-e83.
5. Chi C, Kadir RA. Inherited bleeding disorders in the adolescent female. Best Pract Res Clin Obstet Gynaecol. 2020;63:45-58.
6. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2021;224(1):50-62.

7. O'Brien SH, Zia A. Menorrhagia in adolescents: an algorithmic approach to diagnosis and management. Pediatr Clin North Am. 2022;69(4):725-738.

8. Pecchioli Y, Quint E, Gomez-Lobo V. The utilization of tranexamic acid in pediatric and adolescent gynecology. J Pediatr Adolesc Gynecol. 2023;36(1):14-19.

9. Rimmer E, Rance E, Roberts L. High-dose progestin therapy for acute abnormal uterine bleeding: a clinical analysis. Int J Gynaecol Obstet. 2021;154(2):205-211.

10. Srivaths LV, Minard CG, O'Brien SH. Heavy menstrual bleeding in adolescents: establishing standardized criteria for hospital admission. Blood Adv. 2020;4(15):3677-3684.

11. FIGO Menstrual Disorders Committee. FIGO guidelines on the management of abnormal uterine bleeding. Int J Gynaecol Obstet. 2023;162(2):380-395.

12. Vercellini P, Facchin F, Buggio L, et al. Continuous versus cyclical oral contraceptives for the management of severe dysmenorrhea and heavy menstrual bleeding. Fertil Steril. 2021;115(3):682-690.

13. Bofill Rodriguez M, Dias S, Jordan V, Lethaby A, Lumsden MA. Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD013180.

14. Jain V, Chodankar RR, Nallasamy S, Critchley HO. The levonorgestrel intrauterine system: expanding its utility in the adolescent demographic. Hum Reprod Update. 2021;27(3):472-493.

15. Talepooshan S, Haghjooy Javanmard S. Iron deficiency anemia secondary to heavy menstrual bleeding: neurological and developmental consequences in puberty. J Adolesc Health. 2022;70(5):690-698.